Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893791 | 0.90 | CNR1 (0.71) | CNR1 | |
| SCHEMBL4902857 | 0.88 | CNR1 (0.60) | CNR1 | |
| SCHEMBL4602407 | 0.88 | CNR1 (0.60) | CNR1 | |
| SCHEMBL4616359 | 0.81 | CNR1 (0.48) | CNR1 | |
| SCHEMBL4617902 | 0.80 | CNR1 (0.73) | CNR1 | |
| SCHEMBL4616127 | 0.80 | CNR1 (0.75) | CNR1 | |
| SCHEMBL4638248 | 0.80 | CNR1 (0.59) | CNR1 | |
| SCHEMBL4902164 | 0.79 | CNR1 (0.54) | CNR1 | |
| SCHEMBL4615575 | 0.79 | CNR1 (0.84) | CNR1 | |
| SCHEMBL4892025 | 0.79 | CNR1 (0.70) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1940820-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031721-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | CNR2, CNR1, FAAH | CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.